Compare Merck & Co., Inc. (MRK) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Quantumscape Corp — how do they compare? Merck & Co., Inc. trades at $142.16 (market cap $352.29B), while Quantumscape Corp trades at $4.67 (market cap $2.78B). The key difference: Merck & Co., Inc. is far larger — about 126.7× Quantumscape Corp's market cap, and Merck & Co., Inc. pays a 2.38% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Quantumscape Corp for 37 Days on average.
| MRK | QS | |
|---|---|---|
Market Cap | $352.29B | $2.78B |
Volume | 6,348,796 | 11,236,221 |
Sector | Health | Consumer Cyclical |
52-Week High | $156.43 | $18.44 |
52-Week Low | $82.49 | $4.52 |
Typical Hold Time | 98 Days | 37 Days |
Enterprise Value | $399.05B | $1.99B |
Dividend Yield | 2.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, up 0.33% on the day, with a bearish technical signal but strong analyst support. The company reported revenue of $65.0B in 2025 with a net income margin of 28.07%, though 2026 projections show a sharp decline to 4.76%. Recent acquisition activity includes the tender offer for Terns Pharmaceuticals to bolster its oncology pipeline, while cash flow trends indicate significant investing outflows in 2026.
The outlook is mixed: robust fundamentals and a consensus price target of $159.59 suggest upside, but high valuation ratios (P/E 114.23) and projected earnings volatility pose risks. Investors should weigh strong institutional buying against technical weakness and competitive pressures in the pharma sector.
QuantumScape (QS) trades at $4.58, down 1.51% on the day, with a bearish technical outlook and no current revenue generation. The company reported a net loss of $435.05 million in 2025 and faces significant execution risks as it develops solid-state battery technology. Analyst sentiment is cautious with 73% hold ratings, though the consensus price target of $10.35 suggests potential upside if commercialization milestones are met.
QS represents a high-risk, high-reward opportunity in the pre-revenue EV battery space. The primary investment thesis hinges on successful commercialization of solid-state batteries by 2029, but competition and execution delays pose substantial risks. Current negative ROE of -39.08% and cash burn require careful monitoring of funding runway and partnership developments with automotive manufacturers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
